FOLFOX regimen improved five-year survival in metastatic... HemOncToday, NJ - 8 minutes ago ?The 9.8% five-year survival observed for FOLFOX?treated patients in this trial sets a new benchmark in clinical trials for patients who have metastatic...
Llew Keltner ? Battling solid tumours with light Pharmaceutical Technology Europe, UK - LSO is nearing completion of a Phase III trial in hepatocellular carcinoma (HCC) and is enrolling patients in a Phase III trial for metastatic colorectal ...
New Drug Found Effective for Metastatic RCC Renal and Urology News, NY - Nov 24, 2008 STOCKHOLM ? Patients with advanced renal cell carcinoma (RCC) who are treated with RAD001 after failing standard therapy have more than twice the ...
A study of lymph node ratio in stage IV colorectal cancer 7thSpace Interactive (press release), NY - Known important factors include the extent of the metastasis and the patients' performance status. The lymph node factors are of known importance in earlier ...
Source: Google News
Recent News and Articles on the Keywords: new + metastatic + melanomas Related to the article below (Last Update: 8/7/2008)
GOTTA DO IT Joliet Herald News, IL - Hahn was recently diagnosed with stage 4 metastatic melanoma. Sponsored by Friends in her honor. Donations may be made to Miracles for Mommy, ...
ZymoGenetics Inc. Q2 2008 Earnings Call Transcript Seeking Alpha, NY - Aug 5, 2008 Presentation of IL-21 Phase II interim data in metastatic melanoma at our Investor Day meeting in New York on December 11 th , and in November, ...ZGEN
McCain's Skin Growth Is Not Melanoma Medscape (subscription) - Jul 31, 2008 Treatment options for metastatic melanoma include palliative regional lymphadenectomy and palliative resection ? with occasional long-term survival ? of ...
… macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic … - R Soiffer, T Lynch, M Mihm, K Jung, C Rhuda, JC … - Proceedings of the National Academy of Sciences of the …, 1998 - pubmedcentral.nih.gov ... Figure 3, Figure 3 Melanoma cell lysates were immunoblotted with autologous ... beginning
immunization, these patients had developed multiple newmetastatic lesions ...
Genomic analysis of metastasis reveals an essential role for RhoC - EA Clark, TR Golub, ES Lander, RO Hynes? - Nature, 2000 - Mass Med Soc ... poorly metastaticmelanoma cells into highly metastatic cells simply by ... Molecular
classification of cutaneous malignant melanoma by gene ...New to Journal Watch? ...
… induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic … - GQ Phan, JC Yang, RM Sherry, P Hwu, SL Topalian, … - Proceedings of the National Academy of Sciences, 2003 - National Acad Sciences ... High-Dose Bolus Interleukin-2 in Patients With MetastaticMelanoma Who Have ... CD200
Expression on Tumor Cells Suppresses Antitumor Immunity: New Approaches to ...
… antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: In vivo … - C Yee, JA Thompson, D Byrd, SR Riddell, P Roche, E … - Proceedings of the National Academy of Sciences, 2002 - National Acad Sciences ... T cell infusion, progressive metastatic disease refractory ... appearance of a single new nodule on ... patients presenting with advanced melanoma failing conventional ...
Source: Google Scholar
Paclitaxel and Carboplatin, a new option for patients with metastatic melanoma
Researchers from Mayo Clinic Cancer Center have shown that the combination of Paclitaxel and Carboplatin appears to be effective for metastatic melanoma when traditional treatments have failed.
The study is published in the journal Cancer.
" Melanoma is unfortunately one of the few cancers that has become more common over the last few decades, and when it becomes metastatic, there are very few treatment options," says Ravi Rao, Mayo Clinic oncologist and lead investigator of the study. " This is a good step towards better treating this cancer. “Nearly half of the patients that received Paclitaxel and Carboplatin experienced a clinical benefit of stable disease ( 19 percent ) or tumor size reduction ( 26 percent ).
The National Cancer Institute reports a 2.4 percent increase in the incidence of melanoma between 1992 and 2002. New cases are diagnosed in about 60,000 people each year in the United States, and almost 8,000 die because of metastasized melanoma. Because they know that most therapies provide palliative as opposed to curative options, researchers at Mayo Clinic Cancer Center consider developing more effective curative treatment options to be a priority.
Rao and his co-investigators examined the records of 31 metastatic melanoma patients at Mayo Clinic who were treated with the Paclitaxel and Carboplatin combination between March 2003 and January 2005.
These patients had previously received (and failed) an average of two treatments, including vaccine/immunotherapy. Interestingly, the researchers found that this combination benefited even those patients in whom Temozolomide ( currently the most commonly used chemotherapy drug for melanoma ) failed.
Because the data was collected from the records of patients treated previously and was not part of a set treatment regimen, the schedule and dosage of Paclitaxel and Carboplatin varied. However, the researchers believe that using the drugs weekly ( compared to once every three weeks ) makes the combination more tolerable, and the researchers prefer that option.
